WallStSmart

Merck & Company Inc (MRK)vsRecursion Pharmaceuticals Inc (RXRX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 98648% more annual revenue ($67.38B vs $68.23M). MRK leads profitability with a 3.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 42/100 (D).

MRK

Hold

42

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

RXRX

Hold

35

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -0.84
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-74.0%)

Margin of Safety

-74.0%

Fair Value

$84.93

Current Price

$144.52

$59.59 premium

UndervaluedFair: $84.93Overvalued

Intrinsic value data unavailable for RXRX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$362.27B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Free Cash FlowQuality
$5.52B8/10

Generating 5.5B in free cash flow

RXRX3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
258.5%10/10

Revenue surging 258.5% year-over-year

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
5.5%3/10

ROE of 5.5% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Debt/EquityHealth
1.203/10

Elevated debt levels

RXRX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-54.6%2/10

ROE of -54.6% — below average capital efficiency

Free Cash FlowQuality
$-77.81M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : RXRX

The strongest argument for RXRX centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 258.5% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Bear Case : RXRX

The primary concerns for RXRX are EPS Growth, Profit Margin, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while RXRX is a hypergrowth play — different risk/reward profiles.

RXRX carries more volatility with a beta of 1.15 — expect wider price swings.

RXRX is growing revenue faster at 258.5% — sustainability is the question.

MRK generates stronger free cash flow (5.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (42/100 vs 35/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Recursion Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.

Want to dig deeper into these stocks?